[go: up one dir, main page]

AU2002230764A1 - Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors - Google Patents

Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors

Info

Publication number
AU2002230764A1
AU2002230764A1 AU2002230764A AU3076402A AU2002230764A1 AU 2002230764 A1 AU2002230764 A1 AU 2002230764A1 AU 2002230764 A AU2002230764 A AU 2002230764A AU 3076402 A AU3076402 A AU 3076402A AU 2002230764 A1 AU2002230764 A1 AU 2002230764A1
Authority
AU
Australia
Prior art keywords
imidazolidinones
hepatitis
virus
protease inhibitors
related derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002230764A
Inventor
N Qi Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of AU2002230764A1 publication Critical patent/AU2002230764A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002230764A 2000-12-13 2001-12-12 Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors Abandoned AU2002230764A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25516800P 2000-12-13 2000-12-13
US60/255,168 2000-12-13
PCT/US2001/047916 WO2002048157A2 (en) 2000-12-13 2001-12-12 Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors

Publications (1)

Publication Number Publication Date
AU2002230764A1 true AU2002230764A1 (en) 2002-06-24

Family

ID=22967139

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002230764A Abandoned AU2002230764A1 (en) 2000-12-13 2001-12-12 Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors

Country Status (3)

Country Link
US (1) US6727366B2 (en)
AU (1) AU2002230764A1 (en)
WO (1) WO2002048157A2 (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA66767C2 (en) 1996-10-18 2004-06-15 Вертекс Фармасьютикалс Інкорпорейтед Serine proteases inhibitors, pharmaceutical composition, a method for inhibitining activity and a method for treatment or prevention of viral infection of hepatitis c
SV2003000617A (en) * 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
MXPA04009938A (en) 2002-04-11 2004-12-13 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease.
MY140819A (en) 2002-06-28 2010-01-29 Idenix Caymans Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
TW200418791A (en) * 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
PL2604620T5 (en) 2003-05-30 2024-10-14 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
AR045596A1 (en) 2003-09-05 2005-11-02 Vertex Pharma INHIBITORS OF SERINE PROTEASES IN PARTICULAR HCV PROTEASA NS3-NS4A
MXPA06004006A (en) 2003-10-10 2006-06-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease.
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
EP1711515A2 (en) 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CN101023094B (en) 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
NZ554442A (en) 2004-09-14 2011-05-27 Pharmasset Inc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
AR054778A1 (en) 2005-06-17 2007-07-18 Novartis Ag USE OF SANGLIFERINA IN HCV
EP2256113A1 (en) * 2005-08-02 2010-12-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
CN102382170A (en) 2005-08-19 2012-03-21 弗特克斯药品有限公司 Method for preparation of protease inhibitors and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (en) * 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
KR20080072906A (en) 2005-11-11 2008-08-07 버텍스 파마슈티칼스 인코포레이티드 Hepatitis C Virus Variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
CN101489557B (en) 2006-02-27 2013-12-18 弗特克斯药品有限公司 Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same
KR20080112303A (en) 2006-03-16 2008-12-24 버텍스 파마슈티칼스 인코포레이티드 Deuterated Hepatitis C Protease Inhibitor
BRPI0710878A2 (en) 2006-04-11 2015-03-31 Novartis Ag Organic compounds and their uses
BRPI0710153A2 (en) * 2006-04-11 2011-08-02 Novartis Ag organic compounds and their uses
WO2008106151A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US8575208B2 (en) * 2007-02-27 2013-11-05 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
HRP20110713T1 (en) * 2007-02-28 2011-11-30 Conatus Pharmaceuticals CHRONIC Viral HEPATITIS C TREATMENT PROCEDURES USING RO 113-0830
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
NZ580917A (en) 2007-05-04 2012-06-29 Vertex Pharma Combinations of protease inhibitors such as VX-950 and polymerase inhibitors for the treatment of HCV infection
CA2704284A1 (en) * 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
JP5574982B2 (en) * 2008-02-04 2014-08-20 イデニク プハルマセウティカルス，インコーポレイテッド Macrocyclic serine protease inhibitor
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EP2476690A1 (en) 2008-07-02 2012-07-18 IDENIX Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
EA201100851A1 (en) 2008-12-23 2012-04-30 Фармассет, Инк. NUCLEOSIDE ANALOGUES
EA019341B1 (en) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Nucleoside phosphoramidates
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
EP2403860B1 (en) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
EP2417134B1 (en) 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
KR20120118008A (en) 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
MX2012011171A (en) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Nucleoside phosphoramidates.
AR094621A1 (en) 2010-04-01 2015-08-19 Idenix Pharmaceuticals Inc PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
AU2011311880B2 (en) 2010-10-08 2014-07-24 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
JP6069215B2 (en) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー Compound
CA2821340A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
TW201309690A (en) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
CN103842369A (en) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 Compounds and pharmaceutical compositions for the treatment of viral infections
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
CA2847892A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013082476A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
WO2013133927A1 (en) 2012-02-13 2013-09-12 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
CN104470939B (en) 2012-05-22 2017-04-26 埃迪尼克斯医药有限责任公司 D-amino acid compounds for liver disease
EA030189B8 (en) 2012-10-08 2018-10-31 Иденикс Фармасьютикалз Ллс 2'-chloro nucleoside analogs for hcv infection
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
WO2014078427A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP3038601B1 (en) 2013-08-27 2020-04-08 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
US20170198005A1 (en) 2013-11-27 2017-07-13 Idenix Pharmaceuticals Llc 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
WO2015134780A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2016004280A2 (en) * 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
UA66767C2 (en) 1996-10-18 2004-06-15 Вертекс Фармасьютикалс Інкорпорейтед Serine proteases inhibitors, pharmaceutical composition, a method for inhibitining activity and a method for treatment or prevention of viral infection of hepatitis c
ATE346035T1 (en) 1998-03-31 2006-12-15 Vertex Pharma INHIBITORS OF SERINE PROTEASES, IN PARTICULAR HEPATITIS C VIRUS NS3 PROTEASE
AR034127A1 (en) * 2000-07-21 2004-02-04 Schering Corp IMIDAZOLIDINONES AS INHIBITORS OF NS3-SERINA PROTEASA OF THE HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITION, A METHOD FOR THEIR PREPARATION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Also Published As

Publication number Publication date
US20030100768A1 (en) 2003-05-29
US6727366B2 (en) 2004-04-27
WO2002048157A3 (en) 2003-03-27
WO2002048157A2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
AU2002230764A1 (en) Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
AU2002230763A1 (en) Inhibitors of hepatitis c virus ns3 protease
AU2001245356A1 (en) Inhibitors of hepatitis c virus ns3 protease
AU2055301A (en) Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
AU2001282922A1 (en) Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
AU6371900A (en) Lactam inhibitors of hepatitis c virus ns3 protease
AU2001280640A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
HU229997B1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2003259155A1 (en) Pharmaceutical compositions comprising hepatitis c viral protease inhibitors
IL153669A0 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
GB0107924D0 (en) Inhibitor of hepatitis C virus NS3 protease
IL151934A0 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
EP1292603B8 (en) Methods and compositions for treating hepatitis c virus
WO2004014852A3 (en) Iminothiazolidinones as inhibitors of hcv replication
AU7063598A (en) Hepatitis c ns3 protease inhibitors
IL155842A0 (en) Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus
HUP0500456A3 (en) Hepatitis c tripeptide inhibitors, pharmaceutical compositions comprising thereof and their use
PL373411A1 (en) Hepatitis c virus inhibitors
AU1324300A (en) Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
EP1141255A4 (en) Modified forms of hepatitis c virus ns3 protease
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU2001254670A1 (en) Detection of hepatitis b virus rna
AU2002350322A1 (en) Inhibitors of hepatitis c virus protease
AU2001264856A1 (en) Inhibitors of viral infection